|
OMB
APPROVAL
|
||||
|
OMB
Number: 3235-0145
|
||||
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No. )*
ANCHOR FUNDING SERVICES,
INC.
(Name
of
Issuer)
Common
Stock
(Title
of Class of Securities)
032904
10 4
(CUSIP
Number)
Steven
Morse, Esq., Morse & Morse, PLLC., 1400 Old Country Road, Westbury, NY 11590
(516-487-1446)
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
December
31,
2007
(Date
of
Event which Requires Filing of this Statement)
If
the
filing person has previously filed a statement on Schedule 13G to report the
acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box 9.
Check
the
following box if a fee is being paid with the statement
[ ]. (A fee is not required only if the reporting person:
(1) has a previous statement on file reporting beneficial ownership of more
than
five percent of the class of securities described in Item 1; and (2) has filed
no amendment subsequent thereto reporting beneficial ownership of five percent
or less of such class.) (See Rule 13d-7.)
Note:
Six
copies of this statement, including all exhibits, should be filed with the
Commission. See Rule 13d-1(a) for other parties to whom copies are
sent.
*The
remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed
to
be "filed" for the purpose of Section 18 of the Securities Exchange Act ("ACT")
or otherwise subject to the liabilities of that section of the Act but shall
be
subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page
2 of 7 Pages
|
|
1
|
NAME
OF REPORTING PERSON
S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Frederick
Buechel
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) [__]
(b) [X]
|
|
3
|
SEC
USE ONLY
|
|
4
|
SOURCE
OF FUNDS*
NOT
APPLICABLE
|
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d)
OR 2(e)
|
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
-0-
|
|
8
|
SHARED
VOTING POWER
2,315,084
|
|
|
9
|
SOLE
DISPOSITIVE POWER
|
|
|
10
|
SHARED
DISPOSITIVE POWER
2,000,000
|
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,315,084
|
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
|
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.5%
- Common
dispositive power [11.8% voting power)
|
|
14
|
TYPE
OF REPORTING PERSON*
IN
|
*SEE
INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE
BOTH SIDES OF THE
COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING
EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page 3 of
7 Pages
|
|
1
|
NAME
OF REPORTING PERSON
S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Buechel
Patient Care Research & Education Fund
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) [__]
(b) [X]
|
|
3
|
SEC
USE ONLY
|
|
4
|
SOURCE
OF FUNDS*
NOT
APPLICABLE
|
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d)
OR 2(e)
|
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Florida
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
-0-
|
|
8
|
SHARED
VOTING POWER
1,157,542
|
|
|
9
|
SOLE
DISPOSITIVE POWER
-0-
|
|
|
10
|
SHARED
DISPOSITIVE POWER
1,000,000
|
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,157,542
|
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [X]
Excludes
shares owned by Buechel Family Ltd, Partnership
|
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.23%
-
Common [5.9% voting capital stock)
|
|
14
|
TYPE
OF REPORTING PERSON*
OO
|
*SEE
INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE
BOTH SIDES OF THE
COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING
EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE
ATTESTATION.
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page
4 of 7 Pages
|
|
1
|
NAME
OF REPORTING PERSON
S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Buechel
Family Ltd. Partnership
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A
GROUP*
(a) [__]
(b) [X]
|
|
3
|
SEC
USE ONLY
|
|
4
|
SOURCE
OF FUNDS*
NOT
APPLICABLE
|
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d)
OR 2(e)
|
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Nevada
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
-0-
|
|
8
|
SHARED
VOTING POWER
1,157,542
|
|
|
9
|
SOLE
DISPOSITIVE POWER
-0-
|
|
|
10
|
SHARED
DISPOSITIVE POWER
1,000,000
|
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [X]
Excludes
shares owned by Buechel Patient Care,
Research
and Education Fund
|
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.23
– common [5.9% voting stock]
|
|
14
|
TYPE
OF REPORTING PERSON*
PN
|
*SEE
INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE
BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING
EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page 5 of
7 Pages
|
On
June 29, 2007, the Issuer became a
reporting company under Section 12(g) of the Securities and Exchange Act of
1934, as amended, when its Form 10-SB (filed on April 30, 2007) became effective
(File No. 0-52589). This Schedule 13D is being filed for the reporting person
who was a 5% or greater stockholder at the time that the Form 10-SB became
effective in lieu of a Schedule 13G. For this reason, all references
to source of funds have been answered not applicable.
Item
1. Security
and Issuer
This
statement relates to the Common Stock of Anchor Funding Services, Inc. (the
“Issuer”). The Issuer’s executive office is located at 10801 Johnston
Road, Suite 210, Charlotte, NC 28226
Item
2. Identity
and Background
|
|
(a)
|
Frederick
Buechel
|
(b) 61ST
Street
|
|
South
Orange, NJ 07079
|
|
|
(c)
|
Medical
Doctor (surgeon)
|
(d) Not
applicable.
|
|
(e)
|
Not
applicable.
|
|
|
(f)
|
USA
|
------------
|
|
(a)
|
Buechel
Patient Care Research & Education
Fund*
|
e
|
|
(b)
|
c/o
Frederick Buechel
|
61ST
Street
|
|
South
Orange, NJ 07079
|
|
|
(c)
|
Not
for profit organization (501-c3). Its primary business purpose is
research
and education.
|
(d) Not
applicable.
|
|
(e)
|
Not
applicable.
|
|
|
(f)
|
Florida
|
__________
* Frederick
Buechel may be deemed to control this fund as Mr. Buechel is the Chairman of
the
Board
of
Directors.
------------
|
|
(a)
|
Buechel
Family Ltd. Partnership
|
|
|
General
Partner – Aquavista Corp. which is controlled by Frederick
Buechel
|
| (b) | c/o Oceans & Associates LLC |
| 1645 Village Center Circle Suite 170 |
| Las Vegas, NV 89134 |
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page 6 of
7 Pages
|
|
|
(c)
|
Private
investment entity engaged in the purchase and sale of
securities.
|
(d) Not
applicable.
|
|
(e)
|
Not
applicable.
|
|
|
(f)
|
Nevada
|
Item
3. Source
and Amount of Funds or Other Consideration
Not applicable.
Item
4. Purpose
of Transactions
|
(a)
|
-
(j) Not applicable.
|
This
filing is being made as a result of the effectiveness of the Issuer’s
registration statement on Form 10. Each of the Reporting Persons has acquired
the securities covered by this schedule for investment purposes only. The
Reporting Persons do not have any present plans or proposals that relate to
or
would result in any of the actions required to be described in item 4 of
Schedule 13D. Each of the Reporting Persons may at any time review or reconsider
its position with respect to the Issuer and formulate plans or proposals with
respect to any of such matters, but has no present intention of doing
so.
Item
5. Interest
in Securities of the Issuer
(a)
-
(b) As of December 31, 2007, the Issuer has
outstanding 11,820,555 shares of Common Stock and 1,342,500 shares of Series
1
Preferred Stock with the voting rights of 7,770,000 common shares. Of the
foregoing shares of Common Stock, the reporting persons beneficially own and
have the shared voting power equivalent to 2,315,084 shares of Common Stock,
representing 11.8% of the outstanding voting capital stock and equivalent to
14.5% of the dispositive power over the common stock on a converted basis.
In
this respect, Frederick Buechel shares in the voting power of 2,315,084 shares,
but shares in the dispositive power of 2,000,000 shares. Each of Buechel Patient
Care Research & Education Fund and Buechel Family Ltd. Partnership has a
shared voting power in 1,157,542 shares and the shared dispositive power in
1,000,000 shares. Frederick Buechel may be deemed to control the two other
Reporting Persons and thus shares in the voting power and dispositive power
of
securities indicated herein.
(c) Not
Applicable.
(d)
-
(e) Not Applicable
Item
6. Contracts,
Arrangements, Understandings or Relationships with Respect to the Securities
of
the Issuer.
Not
Applicable.
Item
7. Materials
to be filed as Exhibits
Not
applicable.
SCHEDULE
13D
|
CUSIP
No. 032904 10 4
|
Page 7 of
7 Pages
|
Signature
After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
Dated: January
9, 2008
Signature
By: /s/Frederick Buechel
Frederick
Buechel
BUECHEL
PATIENT CARE, RESEARCH & EDUCATION FUND
By:
Frederick
Buechel
Frederick Buechel, Chairman of the Board
BUECHEL
FAMILY LTD.
PARTNERSHIP
By:
Frederick
Buechel
Aquavista Corp. as General Partner by
Frederick
Buechel as its control person